SMMT logo

Summit Therapeutics (SMMT) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

05 March 2015

Indexes:

Not included

Description:

Summit Therapeutics is a biotechnology company focused on developing innovative treatments for serious diseases. They specialize in antibiotic therapies and are dedicated to addressing unmet medical needs, particularly in areas like muscular dystrophy and infectious diseases, using advanced science and technology.

Events Calendar

Earnings

Next earnings date:

Feb 20, 2025

Recent quarterly earnings:

Oct 30, 2024

Recent annual earnings:

Feb 20, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

18 Nov '24 HC Wainwright & Co.
Buy
04 Nov '24 JMP Securities
Market Outperform
31 Oct '24 HC Wainwright & Co.
Buy
21 Aug '24 HC Wainwright & Co.
Buy
15 Aug '24 HC Wainwright & Co.
Buy
14 Aug '24 HC Wainwright & Co.
Buy
12 Aug '24 HC Wainwright & Co.
Buy
03 June '24 Stifel
Buy
31 May '24 Citigroup
Buy
07 May '24 Citigroup
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Why Summit Therapeutics Stock Was a Winner Today
Why Summit Therapeutics Stock Was a Winner Today
Why Summit Therapeutics Stock Was a Winner Today
SMMT
fool.com04 November 2024

A cancer drug has vast potential for the company, says a pundit newly following it.

Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo
SMMT
benzinga.com04 November 2024

JMP Securities initiated coverage on Summit Therapeutics Inc. SMMT, noting the company's initial focus on infectious disease. Later, in 2022, the company pivoted to oncology and in-licensed ivonescimab (PD-1 X VEGF bispecific) from Akeso for $500 million upfront and $5 billion in potential milestones.

Summit Therapeutics Posts Wider-Than-Expected Loss in Q3, Nil Sales
Summit Therapeutics Posts Wider-Than-Expected Loss in Q3, Nil Sales
Summit Therapeutics Posts Wider-Than-Expected Loss in Q3, Nil Sales
SMMT
zacks.com31 October 2024

SMMT's third-quarter earnings miss estimates. Management also provides updates on the company's pipeline.

Summit Therapeutics Inc. (SMMT) Q3 2024 Earnings Call Transcript
Summit Therapeutics Inc. (SMMT) Q3 2024 Earnings Call Transcript
Summit Therapeutics Inc. (SMMT) Q3 2024 Earnings Call Transcript
SMMT
seekingalpha.com30 October 2024

Summit Therapeutics Inc. (NASDAQ:SMMT ) Q3 2024 Earnings Conference Call October 30, 2024 9:00 AM ET Company Participants Dave Gancarz - Chief Business and Strategy Officer Bob Duggan - Chairman and CEO Maky Zanganeh - CEO and President Manmeet Soni - COO and CFO Allen Yang - Chief Medical Officer Conference Call Participants Mitchell Kapoor - H. C. Wainwright Brad Canino - Stifel Yigal Nochomovitz - Citi Operator Good morning.

Is Summit Therapeutics a Millionaire Maker?
Is Summit Therapeutics a Millionaire Maker?
Is Summit Therapeutics a Millionaire Maker?
SMMT
fool.com27 October 2024

The potential upside of this stock is undeniably meaty.

Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising?
Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising?
Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising?
SMMT
fool.com24 October 2024

This drugmaker's lead candidate could become a top-selling cancer therapy.

Billionaire Israel Englander Just Quietly Took a Stake in This Potentially Lucrative Pharmaceutical Stock. Should You?
Billionaire Israel Englander Just Quietly Took a Stake in This Potentially Lucrative Pharmaceutical Stock. Should You?
Billionaire Israel Englander Just Quietly Took a Stake in This Potentially Lucrative Pharmaceutical Stock. Should You?
SMMT
fool.com22 October 2024

Millennium Management just initiated a position in a small biotech company developing a new cancer drug.

Up 700% This Year, Is It Too Late to Invest in This Stock?
Up 700% This Year, Is It Too Late to Invest in This Stock?
Up 700% This Year, Is It Too Late to Invest in This Stock?
SMMT
https://www.fool.com/investing/2024/10/15/up-700-this-year-is-it-too-late-to-invest-in-this/15 October 2024

The shares have experienced a pullback in the past couple of weeks.

Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit Therapeutics
Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit Therapeutics
Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit Therapeutics
SMMT
fool.com13 October 2024

It's hard to go wrong with either company, but one is more appealing.

3 Things You Need to Know If You Buy Summit Therapeutics Stock Today
3 Things You Need to Know If You Buy Summit Therapeutics Stock Today
3 Things You Need to Know If You Buy Summit Therapeutics Stock Today
SMMT
fool.com12 October 2024

It's easier to invest confidently when you know both the pros and the cons in full.

FAQ

  • What is the primary business of Summit Therapeutics?
  • What is the ticker symbol for Summit Therapeutics?
  • Does Summit Therapeutics pay dividends?
  • What sector is Summit Therapeutics in?
  • What industry is Summit Therapeutics in?
  • What country is Summit Therapeutics based in?
  • When did Summit Therapeutics go public?
  • Is Summit Therapeutics in the S&P 500?
  • Is Summit Therapeutics in the NASDAQ 100?
  • Is Summit Therapeutics in the Dow Jones?
  • When was Summit Therapeutics's last earnings report?
  • When does Summit Therapeutics report earnings?
  • Should I buy Summit Therapeutics stock now?

What is the primary business of Summit Therapeutics?

Summit Therapeutics is a biotechnology company focused on developing innovative treatments for serious diseases. They specialize in antibiotic therapies and are dedicated to addressing unmet medical needs, particularly in areas like muscular dystrophy and infectious diseases, using advanced science and technology.

What is the ticker symbol for Summit Therapeutics?

The ticker symbol for Summit Therapeutics is NASDAQ:SMMT

Does Summit Therapeutics pay dividends?

No, Summit Therapeutics does not pay dividends

What sector is Summit Therapeutics in?

Summit Therapeutics is in the Healthcare sector

What industry is Summit Therapeutics in?

Summit Therapeutics is in the Biotechnology industry

What country is Summit Therapeutics based in?

Summit Therapeutics is headquartered in United States

When did Summit Therapeutics go public?

Summit Therapeutics's initial public offering (IPO) was on 05 March 2015

Is Summit Therapeutics in the S&P 500?

No, Summit Therapeutics is not included in the S&P 500 index

Is Summit Therapeutics in the NASDAQ 100?

No, Summit Therapeutics is not included in the NASDAQ 100 index

Is Summit Therapeutics in the Dow Jones?

No, Summit Therapeutics is not included in the Dow Jones index

When was Summit Therapeutics's last earnings report?

Summit Therapeutics's most recent earnings report was on 30 October 2024

When does Summit Therapeutics report earnings?

The next expected earnings date for Summit Therapeutics is 20 February 2025

Should I buy Summit Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions